Osteoarthritis - Pipeline Review, H1 2016

Published: Mar, 2016 | Pages: 308 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Osteoarthritis - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Osteoarthritis - Pipeline Review, H1 2016', provides an overview of the Osteoarthritis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Osteoarthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteoarthritis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Osteoarthritis
- The report reviews pipeline therapeutics for Osteoarthritis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Osteoarthritis therapeutics and enlists all their major and minor projects
- The report assesses Osteoarthritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Osteoarthritis

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Osteoarthritis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Osteoarthritis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 8
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Osteoarthritis Overview 12
Therapeutics Development 13
Pipeline Products for Osteoarthritis - Overview 13
Pipeline Products for Osteoarthritis - Comparative Analysis 14
Osteoarthritis - Therapeutics under Development by Companies 15
Osteoarthritis - Therapeutics under Investigation by Universities/Institutes 21
Osteoarthritis - Pipeline Products Glance 22
Late Stage Products 22
Clinical Stage Products 23
Early Stage Products 24
Osteoarthritis - Products under Development by Companies 25
Osteoarthritis - Products under Investigation by Universities/Institutes 32
Osteoarthritis - Companies Involved in Therapeutics Development 33
A. Menarini Industrie Farmaceutiche Riunite Srl 33
AbbVie Inc. 34
Abiogen Pharma S.p.A. 35
Ablynx NV 36
Achelios Therapeutics, Inc. 37
Addex Therapeutics Ltd 38
Akari Therapeutics, Plc 39
Amura Holdings Limited 40
Arcarios BV 41
Asahi Kasei Pharma Corp. 42
Asklepios BioPharmaceutical, Inc. 43
Astellas Pharma Inc. 44
Asterias Biotherapeutics, Inc. 45
Axsome Therapeutics, Inc. 46
Biopharm GmbH 47
Can-Fite BioPharma Ltd. 48
Cara Therapeutics, Inc. 49
Cardax Pharmaceuticals, Inc. 50
Cellceutix Corporation 51
Cellular Biomedicine Group, Inc. 52
Chong Kun Dang Pharmaceutical Corp. 53
Dong-A ST Co., Ltd. 54
Eli Lilly and Company 55
Evgen Pharma PLC 56
Galapagos NV 57
Genequine Biotherapeutics GmbH 58
GlaxoSmithKline Plc 59
IntelliCell BioSciences Inc. 60
Jeil Pharmaceutical Co., Ltd. 61
Jenrin Discovery, Inc. 62
K-Stemcell Co., Ltd. 63
Levolta Pharmaceuticals, Inc. 64
Medivir AB 65
Merck KGaA 66
Mesoblast Limited 67
Mor Research Application Ltd 68
NicOx S.A. 69
Nordic Bioscience A/S 70
Novartis AG 71
Ocata Therapeutics, Inc. 72
Omeros Corporation 73
Ono Pharmaceutical Co., Ltd. 74
OrthoCyte Corporation 75
Osteologix Holdings Plc 76
Pfizer Inc. 77
Pharmalink AB 78
PLx Pharma Inc. 79
ProteoThera, Inc. 80
Regeneus Ltd 81
ReqMed Company, Ltd. 82
Sanofi 83
Seikagaku Corporation 84
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. 85
STELIS Biopharma Pvt. Ltd. 86
Stempeutics Research Private Limited 87
Symic Biomedical, Inc. 88
Takeda Pharmaceutical Company Limited 89
TissueGene, Inc. 90
Upsher-Smith Laboratories, Inc. 91
Yooyoung Pharmaceutical Co., Ltd. 92
Yuhan Corporation 93
Yungjin Pharm. Co., Ltd. 94
Zimmer Biomet Holdings, Inc. 95
Zynerba Pharmaceuticals, Inc. 96
Osteoarthritis - Therapeutics Assessment 97
Assessment by Monotherapy Products 97
Assessment by Combination Products 98
Assessment by Target 99
ssessment by Mechanism of Action 103
Assessment by Route of Administration 106
Assessment by Molecule Type 108
Drug Profiles 110
(apocynin + paeonol) - Drug Profile 110
(clodronate disodium + hyaluronic acid) - Drug Profile 111
ABT-981 - Drug Profile 112
AlloJoin - Drug Profile 113
AM-3701 - Drug Profile 114
AM-3876 - Drug Profile 115
Anatabine - Drug Profile 116
Antibody for Osteoarthritis - Drug Profile 118
Antibody to Inhibit TGF-Beta 1 for Osteoarthritis - Drug Profile 119
ARC-118 - Drug Profile 120
AS-001 - Drug Profile 121
ASP-7962 - Drug Profile 122
BNP-OA - Drug Profile 123
BRM-421 - Drug Profile 124
CDX-085 - Drug Profile 125
celecoxib - Drug Profile 127
CHND-1 - Drug Profile 128
CKD-941 - Drug Profile 130
clodronate disodium - Drug Profile 131
CR-8357 - Drug Profile 132
CR-845 - Drug Profile 133
CRB-0017 - Drug Profile 136
CS-30MS02 - Drug Profile 137
DA-5202 - Drug Profile 138
DIS-BIO-EPS - Drug Profile 139
DNX-314 - Drug Profile 140
Drug for Bone Diseases and Osteoarthritis - Drug Profile 141
Drug for Osteoarthritis - Drug Profile 142
Drugs to Inhibit Renin Angiotensin for Osteoarthritis - Drug Profile 143
Drugs to Modulate Bone Morphogenetic Protein for Osteoarthritis and Fracture - Drug Profile 144
Drugs to Modulate PPAR-Delta for Immunology, Metabolic and Musculoskeletal Disorders - Drug Profile 145
duloxetine hydrochloride DR - Drug Profile 146
fasitibant chloride - Drug Profile 148
GLPG-1972 - Drug Profile 149
GQ-203 - Drug Profile 150
GQ-303 - Drug Profile 151
GSK-2394002 - Drug Profile 152
GZ-389988 - Drug Profile 153
JD-4000 Series - Drug Profile 154
Kartogenin - Drug Profile 155
KBP-056 - Drug Profile 156
ketoprofen - Drug Profile 157
KM-278 - Drug Profile 159
LEVI-04 - Drug Profile 160
LH-023 - Drug Profile 161
LNA-043 - Drug Profile 162
MIV-711 - Drug Profile 163
Monoclonal Antibodies for Inflammation and Osteoarthritis - Drug Profile 164
Monoclonal Antibody for Osteoarthritis - Drug Profile 166
MOR-106 - Drug Profile 167
MSBCAR-001 - Drug Profile 168
naproxcinod - Drug Profile 169
NBS-101 - Drug Profile 171
NStride APS - Drug Profile 172
OAX-1 - Drug Profile 173
ONO-4474 - Drug Profile 174
OTXCP-03 - Drug Profile 175
OTXCP-07 - Drug Profile 176
pentosan polysulfate sodium - Drug Profile 177
Peptide for Osteoarthritis - Drug Profile 179
piclidenoson - Drug Profile 180
PL-1100 - Drug Profile 182
PRO-1 - Drug Profile 183
Progenza - Drug Profile 185
Protein for Osteoarthritis - Drug Profile 186
Protein for Osteoarthritis and Asthma - Drug Profile 187
Protein for Rheumatoid Arthritis and Osteoarthritis - Drug Profile 188
Protein to Activate BMP-7 for Obesity, Osteoarthritis, Kidney Fibrosis and Alport Syndrome - Drug Profile 189
PRX-167700 - Drug Profile 191
Recombinant Peptides for Osteoarthritis - Drug Profile 192
Recombinant Protein to Activate IL-4 and IL-10 Receptors for Osteoarthritis and CNS - Drug Profile 193
Recombinant Protein to Agonize IGF-1 Receptor for Osteoarthritis - Drug Profile 194
Recombinant Protein to Agonize PTH Receptor for Osteoporosis and Osteoarthritis - Drug Profile 195
ReJoin - Drug Profile 196
Salmon Calcitonin - Drug Profile 197
SAR-396049 - Drug Profile 199
SB-061 - Drug Profile 200
SBL-005 - Drug Profile 201
SI-613 - Drug Profile 202
SM-04690 - Drug Profile 203
Small Molecule for Degenerative Arthritis - Drug Profile 204
Small Molecule for Osteoarthritis - Drug Profile 205
Small Molecule to Agonize A2A for Immunology, Hematological and Neurological Disorders - Drug Profile 206
Small Molecule to Inhibit MMP13 for Osteoarthritis - Drug Profile 207
Small Molecule to Target GPR22 for Anxiety, Cardiovascular Diseases and Osteoarthritis - Drug Profile 208
Small Molecules for Immunology, Metabolic and Musculoskeletal Disorders - Drug Profile 209
Small Molecules for Immunology, Musculoskeletal and Metabolic Disorders - Drug Profile 210
Small Molecules for Osteoarthritis - Drug Profile 211
Small Molecules to Antagonize TNFR1 for Immunology, Gastrointestinal, Neurology and Hematological Disorders - Drug Profile 212
Small Molecules to Inhibit ADAMTS-5 for Osteoarthritis - Drug Profile 213
Small Molecules to Inhibit Complement System Protein for Osteoarthritis - Drug Profile 214
Small Molecules to Inhibit Kinase for Osteoarthritis and Osteoporosis - Drug Profile 215
Small Molecules to Inhibit MMP-13 for Osteoarthritis - Drug Profile 216
sprifermin - Drug Profile 217
Stem Cell Therapy for Autoimmune Diseases - Drug Profile 219
Stem Cell therapy for CNS, CVS, Dermatological, Immnuological and Metabolic Disorders - Drug Profile 220
Stem Cell Therapy for Degenerative Arthritis - Drug Profile 221
Stem Cell Therapy for Knee Osteoarthritis - Drug Profile 222
Stem Cell Therapy for Multiple Sclerosis, Rheumatoid Arthritis, Osteoarthritis, Autism, Bronchopulmonary Dysplasia, Heart Failure and Cerebral Palsy - Drug Profile 223
Stem Cell Therapy for Osteoarthritis - Drug Profile 225
Stem Cell Therapy for Osteoarthritis, Diabetes Mellitus, Acute Liver Failure, Post Cardiopulmonary Resuscitation and Neurodegenerative Diseases - Drug Profile 226
Stempeucel - Drug Profile 228
Stromal Cell Therapy for Arthritis - Drug Profile 231
Sulforadex - Drug Profile 232
tonogenchoncel-L - Drug Profile 234
TPX-100 - Drug Profile 236
TRBN-0224 - Drug Profile 237
UGP-302 - Drug Profile 238
VOLT-01 - Drug Profile 240
X-0002 - Drug Profile 241
XT-101 - Drug Profile 243
XT-150 - Drug Profile 244
YH-14619 - Drug Profile 245
YRA-1909 - Drug Profile 246
YY-1201 - Drug Profile 247
zoledronic acid - Drug Profile 248
ZYN-002 - Drug Profile 250
Osteoarthritis - Recent Pipeline Updates 251
Osteoarthritis - Dormant Projects 281
Osteoarthritis - Discontinued Products 290
Osteoarthritis - Product Development Milestones 292
Featured News & Press Releases 292
Appendix 299
Methodology 299
Coverage 299
Secondary Research 299
Primary Research 299
Expert Panel Validation 299
Contact Us 299
Disclaimer 300

List of Tables

Number of Products under Development for Osteoarthritis, H1 2016 21
Number of Products under Development for Osteoarthritis - Comparative Analysis, H1 2016 22
Number of Products under Development by Companies, H1 2016 23
Number of Products under Development by Companies, H1 2016 (Contd..1) 24
Number of Products under Development by Companies, H1 2016 (Contd..2) 25
Number of Products under Development by Companies, H1 2016 (Contd..3) 26
Number of Products under Development by Companies, H1 2016 (Contd..4) 27
Number of Products under Development by Companies, H1 2016 (Contd..5) 28
Number of Products under Investigation by Universities/Institutes, H1 2016 29
Comparative Analysis by Late Stage Development, H1 2016 30
Comparative Analysis by Clinical Stage Development, H1 2016 31
Comparative Analysis by Early Stage Development, H1 2016 32
Products under Development by Companies, H1 2016 33
Products under Development by Companies, H1 2016 (Contd..1) 34
Products under Development by Companies, H1 2016 (Contd..2) 35
Products under Development by Companies, H1 2016 (Contd..3) 36
Products under Development by Companies, H1 2016 (Contd..4) 37
Products under Development by Companies, H1 2016 (Contd..5) 38
Products under Development by Companies, H1 2016 (Contd..6) 39
Products under Investigation by Universities/Institutes, H1 2016 40
Osteoarthritis - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2016 41
Osteoarthritis - Pipeline by AbbVie Inc., H1 2016 42
Osteoarthritis - Pipeline by Abiogen Pharma S.p.A., H1 2016 43
Osteoarthritis - Pipeline by Ablynx NV, H1 2016 44
Osteoarthritis - Pipeline by Achelios Therapeutics, Inc., H1 2016 45
Osteoarthritis - Pipeline by Addex Therapeutics Ltd, H1 2016 46
Osteoarthritis - Pipeline by Akari Therapeutics, Plc, H1 2016 47
Osteoarthritis - Pipeline by Amura Holdings Limited, H1 2016 48
Osteoarthritis - Pipeline by Arcarios BV, H1 2016 49
Osteoarthritis - Pipeline by Asahi Kasei Pharma Corp., H1 2016 50
Osteoarthritis - Pipeline by Asklepios BioPharmaceutical, Inc., H1 2016 51
Osteoarthritis - Pipeline by Astellas Pharma Inc., H1 2016 52
Osteoarthritis - Pipeline by Asterias Biotherapeutics, Inc., H1 2016 53
Osteoarthritis - Pipeline by Axsome Therapeutics, Inc., H1 2016 54
Osteoarthritis - Pipeline by Biopharm GmbH, H1 2016 55
Osteoarthritis - Pipeline by Can-Fite BioPharma Ltd., H1 2016 56
Osteoarthritis - Pipeline by Cara Therapeutics, Inc., H1 2016 57
Osteoarthritis - Pipeline by Cardax Pharmaceuticals, Inc., H1 2016 58
Osteoarthritis - Pipeline by Cellceutix Corporation, H1 2016 59
Osteoarthritis - Pipeline by Cellular Biomedicine Group, Inc., H1 2016 60
Osteoarthritis - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 61
Osteoarthritis - Pipeline by Dong-A ST Co., Ltd., H1 2016 62
Osteoarthritis - Pipeline by Eli Lilly and Company, H1 2016 63
Osteoarthritis - Pipeline by Evgen Pharma PLC, H1 2016 64
Osteoarthritis - Pipeline by Galapagos NV, H1 2016 65
Osteoarthritis - Pipeline by Genequine Biotherapeutics GmbH, H1 2016 66
Osteoarthritis - Pipeline by GlaxoSmithKline Plc, H1 2016 67
Osteoarthritis - Pipeline by IntelliCell BioSciences Inc., H1 2016 68
Osteoarthritis - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2016 69
Osteoarthritis - Pipeline by Jenrin Discovery, Inc., H1 2016 70
Osteoarthritis - Pipeline by K-Stemcell Co., Ltd., H1 2016 71
Osteoarthritis - Pipeline by Levolta Pharmaceuticals, Inc., H1 2016 72
Osteoarthritis - Pipeline by Medivir AB, H1 2016 73
Osteoarthritis - Pipeline by Merck KGaA, H1 2016 74
Osteoarthritis - Pipeline by Mesoblast Limited, H1 2016 75
Osteoarthritis - Pipeline by Mor Research Application Ltd, H1 2016 76
Osteoarthritis - Pipeline by NicOx S.A., H1 2016 77
Osteoarthritis - Pipeline by Nordic Bioscience A/S, H1 2016 78
Osteoarthritis - Pipeline by Novartis AG, H1 2016 79
Osteoarthritis - Pipeline by Ocata Therapeutics, Inc., H1 2016 80
Osteoarthritis - Pipeline by Omeros Corporation, H1 2016 81
Osteoarthritis - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 82
Osteoarthritis - Pipeline by OrthoCyte Corporation, H1 2016 83
Osteoarthritis - Pipeline by Osteologix Holdings Plc, H1 2016 84
Osteoarthritis - Pipeline by Pfizer Inc., H1 2016 85
Osteoarthritis - Pipeline by Pharmalink AB, H1 2016 86
Osteoarthritis - Pipeline by PLx Pharma Inc., H1 2016 87
Osteoarthritis - Pipeline by ProteoThera, Inc., H1 2016 88
Osteoarthritis - Pipeline by Regeneus Ltd, H1 2016 89
Osteoarthritis - Pipeline by ReqMed Company, Ltd., H1 2016 90
Osteoarthritis - Pipeline by Sanofi, H1 2016 91
Osteoarthritis - Pipeline by Seikagaku Corporation, H1 2016 92
Osteoarthritis - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H1 2016 93
Osteoarthritis - Pipeline by STELIS Biopharma Pvt. Ltd., H1 2016 94
Osteoarthritis - Pipeline by Stempeutics Research Private Limited, H1 2016 95
Osteoarthritis - Pipeline by Symic Biomedical, Inc., H1 2016 96
Osteoarthritis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 97
Osteoarthritis - Pipeline by TissueGene, Inc., H1 2016 98
Osteoarthritis - Pipeline by Upsher-Smith Laboratories, Inc., H1 2016 99
Osteoarthritis - Pipeline by Yooyoung Pharmaceutical Co., Ltd., H1 2016 100
Osteoarthritis - Pipeline by Yuhan Corporation, H1 2016 101
Osteoarthritis - Pipeline by Yungjin Pharm. Co., Ltd., H1 2016 102
Osteoarthritis - Pipeline by Zimmer Biomet Holdings, Inc., H1 2016 103
Osteoarthritis - Pipeline by Zynerba Pharmaceuticals, Inc., H1 2016 104
Assessment by Monotherapy Products, H1 2016 105
Assessment by Combination Products, H1 2016 106
Number of Products by Stage and Target, H1 2016 108
Number of Products by Stage and Mechanism of Action, H1 2016 112
Number of Products by Stage and Route of Administration, H1 2016 115
Number of Products by Stage and Molecule Type, H1 2016 117
Osteoarthritis Therapeutics - Recent Pipeline Updates, H1 2016 259
Osteoarthritis - Dormant Projects, H1 2016 289
Osteoarthritis - Dormant Projects (Contd..1), H1 2016 290
Osteoarthritis - Dormant Projects (Contd..2), H1 2016 291
Osteoarthritis - Dormant Projects (Contd..3), H1 2016 292
Osteoarthritis - Dormant Projects (Contd..4), H1 2016 293
Osteoarthritis - Dormant Projects (Contd..5), H1 2016 294
Osteoarthritis - Dormant Projects (Contd..6), H1 2016 295
Osteoarthritis - Dormant Projects (Contd..7), H1 2016 296
Osteoarthritis - Dormant Projects (Contd..8), H1 2016 297
Osteoarthritis - Discontinued Products, H1 2016 298
Osteoarthritis - Discontinued Products (Contd..1), H1 2016 299